The HUGO Mutation Database Initiative
The HUGO Mutation Database Initiative
复制标题
DOI：
10.1038/sj.tpj.6500070
复制
发表时间：
2002-01-01
影响因子：
2.8
通讯作者：
Horaitis, O.
中科院分区：
文献类型：
--
作者：
Cotton, R. G. H.;Horaitis, O.
药物基因组学期刊Teins的表达在感染后在病原体中发生变化，为抗菌化疗提供了额外的靶点。了解宿主的相同信息可以提供额外的靶点，可以评估这些靶点以帮助宿主抵御感染，例如通过调节先天免疫反应或阻止不适当的炎症。这些知识将首先在实验室中出现，寻找相关性将需要时间。然而，一旦建立了相关性，就有两条直接的途径可用：筛查以识别阻止感染的病原体，以及开发快速、高度特异的诊断方法来评估病原体种群。基因组学、药物基因组学和蛋白质组学是在抗感染药物发现方面提供巨大前景的技术。有效使用这些技术的关键是超越目前的研究范式，即识别一种能够杀死或防止感染性病原体生长的化合物。相反，这些技术为我们提供了数十个、如果不是数百个新的抗感染靶点的可能性--从病原体对治疗的反应的基因调节和表达，到宿主对治疗的反应的基因调节和表达。
The Pharmacogenomics Journal teins’ expression are changed in the pathogen upon infection provides additional targets for antimicrobial chemotherapy. Knowing that same information for the host offers additional targets that can be assessed to help the host fight off an infection, eg by regulating the innate immune response or blocking inappropriate inflammation. This knowledge will occur first in the laboratory, and the hunt for correlations will take time. Once correlations are established, though, there are two immediate paths available: screening to identify agents to stop the infection and development of rapid, highly specific diagnostics to assess the pathogen population.Genomics, pharmacogenomics, and proteomics are technologies that offer tremendous promise in anti-infective drug discovery. The key to productively using these technologies is to think beyond the current research paradigm ie, identify a compound that kills or prevents the infective agent from growing. Instead, these technologies give us the potential for tens, if not hundreds, of novel anti-infective targets—from the pathogen’s gene regulation and expression in response to therapy, to the host’s gene regulation and expression in response to